Danaher Corporation
DHRHealthcareNASDAQDiagnostics & Research · Last scanned Oct 27, 2026
Scan Results
Daily timeframeDanaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. With a market capitalization of $163.77B, it sits in large-cap territory. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Market Cap
$163.77B
Beta
0.80
P/E (TTM)
38.57
P/E (Fwd)
25.00
EPS (TTM)
$6.04
EPS (Fwd)
$9.32
ROE
8.2%
ROA
4.1%
Cash
$5.68B
Total Debt
$27.78B
Free CF
$4.75B
52W Change
5.4%
Annual Financials
Cash vs Debt
Where DHR stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, DHR finished 17.52% above its 150-day moving average ($194.90) and 14.17% above its 200-day moving average ($200.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DHR overbought or oversold?
At the October 19, 2026 close, DHR's RSI(14) was 52.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $5.68B in cash, though total debt stands at $27.78B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $4.75B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 8.2%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $26.64B (2022) to $24.57B (2025).
As with any equity investment, DHR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Danaher Corporation's trajectory.